Chapter 12 Primates
Agent | Dosage | Species/Comments |
---|---|---|
Amikacin | 2.3 mg/kg IM q24h3,65,145 | Lemurs, chimpanzees |
5 mg/kg IM q8h3 | ||
Amoxicillin | 6.7-13.3 mg/kg PO, IM q8h3,19 | |
11 mg/kg PO q12h39 | ||
11 mg/kg SC, IM q24h39 | ||
15 mg/kg SC q48h × 3 treatments58 | Macaques/depot form | |
500 mg/animal PO, IM, IV3 | Chimpanzees | |
Amoxicillin trihydrate, clavulanic potassium | 6.5-13.5 mg/kg PO q8h19 | Macaques |
13.75 mg/kg PO q12h3 | Chimpanzees | |
15 mg/kg PO q12h135 | ||
62.5 mg PO q12h101 | Lemurs | |
Amphotericin B | 0.25-1 mg/kg IV q24h67 | |
Ampicillin | 20 mg/kg PO, IM, IV q8h3,67 | Chimpanzees |
25-50 mg/kg/day IM, IV divided q6-8h3,19 | ||
50-100 mg/kg IM q12h × 7-10 days65 | ||
Azithromycin | 5-10 mg/kg PO q24h3 | Chimpanzees |
20 mg/kg PO q24h77 | Macaques/Lawsonia intracellularis | |
25-50 mg/kg SC q24h × 7 days112 | Macaques/antimalarial | |
40 mg/kg SC, IM once, then 20 mg/kg q24h × 2-5 days19 | ||
Cefazolin sodium | 25 mg/kg IM, IV q12h × 7-10 days19,65 | Macaques, chimpanzees |
Cefotaxime | 50 mg/kg IM, IV q8h18 | |
100-200 mg/kg IV q6-8h107 | ||
1 g/animal IM, IV q6-12h3 | Chimpanzees | |
Ceftazidime | 50 mg/kg IM, IV q8h29 | Lemurs |
Ceftizoxime (Cefizox, Fujisawa) | 75-100 mg/kg IM q12h × 7 days65 | |
Ceftriaxone | 10 mg/kg IV131 | Macaques, chimpanzees/PD |
50 mg/kg IM q24h3,19 | Macaques | |
50-100 mg/kg IM, IV q12-24h107 | Great apes/bacterial meningitis; excellent penetration into cerebrospinal fluid; transient, self-limiting diarrhea is a side effect | |
Cephalexin | 20 mg/kg PO q12h32 | |
30 mg/kg PO q12h3,19 | ||
Cephaloridine | 20 mg/kg IM q12h32 | |
Cephalothin | 25 mg/kg IM q12h121 | |
Chloramphenicol palmitate | 25 mg/kg PO q8h3 | Infants |
50 mg/kg PO q12h32 | ||
Chloramphenicol sodium succinate | 20 mg/kg IM q12h3,39 | |
33 mg/kg IM q8h3 | ||
50-100 mg/kg SC, IM, IV q8h51,67 | ||
110 mg/kg IM q6h × 5-10 days51 | Pneumococcal meningoenceph-alitis | |
Ciprofloxacin | 10 mg/kg PO q12h3,19 | |
10-25 mg/kg PO q12h58 | ||
16-20 mg/kg PO q12h65 | Macaques/based on PD dosage below;75 suspension of crushed tablets in water | |
250 mg/animal PO once, then 125 mg q12h75 | Macaques/PD (5.1-13 kg animals) | |
Clarithromycin | 10 mg/kg PO q12h × 7 days25 | |
10 mg/kg PO q12h × 10 days25 | Macaques/treatment of Helicobacter pylori infection; part of quadruple therapy with omeprazole, amoxicillin, and bismuth subsalicylate | |
20 mg/kg PO q24h5 | Macaques/PD | |
250-500 mg/animal PO q12h3 | Chimpanzees | |
Clindamycin | 10 mg/kg PO q12h135 | |
12.5 mg/kg IM q8h32 | ||
150-300 mg/animal PO q6h3 | Chimpanzees | |
300-600 mg/animal IM q8-12h3 | Chimpanzees | |
Doxycycline | 2.5 mg/kg PO q12h × 1 day, then 2.5 mg/kg PO q24h3 | |
3-4 mg/kg PO q12h65 | Macaques/based on PD dosage below75 | |
5 mg/kg PO q12h19 | ||
60 mg/animal PO once, then 30 mg/animal q12h75 | Macaques/PD (5.1-13 kg animals) | |
Enrofloxacin (Baytril, Bayer) | 5 mg/kg PO, IM q24h × 10 days6,33,53 | Most species/Shigella flexneri; injectable form given PO |
5 mg/kg nasogastric or orogastric intubation q24h × 10 days85 | Macaques/PD; Shigella gastroenteritis | |
5 mg/kg PO, IM q12-24h3 | ||
Erythromycin | 35 mg/kg PO q8h3 | |
40 mg/kg PO, IM q8-12h18 | ||
75 mg/kg PO q12h × 10 days65 | Most species/Campylobacter-associated diarrhea | |
Erythromycin ethyl-succinate (pediatric suspension; EryPed Drops, Abbott) | 20 mg/kg PO q12h116 | Tamarins/clostridial enteritis |
Ethambutol | 22.5 mg/kg PO q24h146 | Macaques/mycobacteriosis; treat concurrently with isoniazid and rifampin; reduce to 15 mg/kg after 6 wk; continue treatment for 1 yr; treatment of tuberculosis in non-human primates is controversial due to the inability to eliminate carrier state and potential of drug resistance73 |
Fluconazole | 2-3 mg/kg PO q24h × 30 days47 | Macaques/coccidioidomycosis; prolonged treatment is necessary; relapses may occur |
18 mg/kg PO q24h8 | Swamp monkeys/systemic mycoses; treat concurrently with flucytosine; may be effective as a sole agent | |
Flucytosine (Ancobon, Roche) | 50-150 mg/kg/day PO divided q6h3 | Chimpanzees |
143 mg/kg PO q24h8 | Swamp monkeys/systemic mycoses; treat concurrently with fluconazole | |
Furazolidone | 5 mg/kg PO q6h × 7 days65 | |
10 mg/kg PO q12h3 | ||
10-15 mg/kg PO q24h95 | ||
20-40 mg/kg PO q6h67 | ||
100 mg/animal PO q6h3 | Chimpanzees | |
Gentamicin | 1-2 mg/kg IM, IV q8h × 5-7 days65 | |
2-3 mg/kg IM, IV q12h × 5-7 days65 | ||
2-4 mg/kg IM q12h3 | ||
3 mg/kg IM q6-8h140 | Baboons/PD | |
Griseofulvin | 20 mg/kg PO q24h67 | |
200 mg/kg PO once q10d67 | ||
500 mg/day PO divided q6-24h3 | Chimpanzees | |
Imipenem | 10 mg/kg IV131 | Macaques, chimpanzees/PD |
25 mg/kg IV q12h36 | Infuse over 30 min | |
500-1000 mg IM, IV q8h132 | Chimpanzees/methicillin resistant Staphylococcus aureus | |
Isoniazid | 5 mg/kg PO q24h3 | |
15 mg/kg PO q24h146 | Macaques/mycobacteriosis; treat concurrently with ethambutol and rifampin; reduce to 10 mg/kg after 6 wk; continue treatment for 1 yr; supplement with pyridoxine; prophylatic use of isoniazid is controversial; treatment may mask infection and prevent detection by tuberculin skin testing; isoniazid has been associated with false negative tuberculin skin testing results73 | |
30-50 mg/kg PO q24h3 | Chimpanzees/active TB test for 9 mo; prophylaxis: 300 mg/day PO | |
Itraconazole | 10 mg/kg PO q24h | Fungal (yeast) gastroenteritis |
Kanamycin | 7.5 mg/kg IM q12h67 | |
Ketoconazole | 5-10 mg/kg PO q12h3,18 | Candidiasis |
200-400 mg/day PO3 | Chimpanzees | |
Lincomycin | 5-10 mg/kg IM q12h65 | |
Methicillin sodium | 50 mg/kg IM q12h × 7 days51 | |
Metronidazole | 12.5-15 mg/kg PO q12h64 | Clostridium; used in conjunction with tylosin |
25 mg/kg PO q12h99 | Colobinae/gastroenteritis | |
50 mg/kg PO or via orogastric tubing q24h18 | Macaques/gastroenteritis; inflammatory bowel disease | |
Minocycline | 2 mg/kg PO q12h70 | Prosimians |
15 mg/kg PO q12h × 7 days65,72 | Lemurs72 | |
Neomycin | 10 mg/kg PO q12h32 | |
50 mg/kg PO q12h3 | ||
Nitrofurantoin | 2-4 mg/kg IM, IV q8h67 | |
Nitrofurazone | 11 mg/kg PO q24h51 | |
Norfloxacin (Noroxin, Roberts) | 25 mg/kg via nasogastric intubation q12h43 | Macaques/PD |
25-30 mg/kg PO q12h116 | Tamarins | |
Nystatin | 100,000 U/animal PO q8h3,19 | |
200,000 U/animal PO q6h39 | Gastrointestinal candidiasis; continue 48 hr after clinical recovery | |
500,000 -1,000,000 U/animal PO q8h3 | Chimpanzees | |
Oxacillin | 16.5 mg/kg SC, IM q8h18 | |
Oxytetracycline | 10 mg/kg SC, IM q24h32,135 | |
250-300 mg/day PO, IM divided q8-24h3 | Chimpanzees | |
Penicillin G, benzathine | 20,000-60,000 U/kg SC, IM q24h18 | |
40,000 U/kg IM q72h67 | ||
Penicillin G, procaine | 20,000 U/kg IM q12h67 | |
20,000-40,000 U/kg SC, IM q12h18 | Macaques, squirrel monkeys | |
22,000 U/kg IM q24h3 | Chimpanzees | |
50,000-60,000 U/kg SC, IM q24h101 | Lemurs | |
Piperacillin sodium | 80-100 mg/kg IM, IV q8h × 7-10 days65 | |
100-150 mg/kg IM, IV q12h65 | ||
Rifampin | 22.5 mg/kg PO q24h146 | Macaques/mycobacteriosis; treat concurrently with ethambutol and isoniazid; reduce to 15 mg/kg after 6 wk; continue treatment for 1 yr; controversial because of the public health danger and the induction of potential drug resistant strains73 |
600 mg PO, IV q24h3 | Chimpanzees | |
Sulfamethazine | 66 mg/kg PO q12h20 | |
Sulfasalazine | — | Gastrointestinal antibacterial and antiinflammatory properties |
20 mg/kg PO q24h × 28 days, then 40 mg/kg PO q24h prn102 | Western lowland gorillas/reactive arthritis | |
30 mg/kg PO q12h61 | Spider monkeys | |
50 mg/kg PO q24h × 10 wk91 | Cotton-top tamarins/chronic colitis | |
Sulfisoxazole | 50 mg/kg PO q24h58 | Macaques |
Tetracycline | 20-25 mg/kg PO q8-12h × 7-10 days3,65 | Most species |
25 mg/kg IM, IV q12h65 | ||
Trimethoprim/sulfa | 24 mg/kg PO q12h39 | |
25 mg/kg SC, IM q24h29 | Lemurs | |
27 mg/kg SC q24h39 | ||
50 mg/kg PO q12h29 | Lemurs | |
Trimethoprim/sulfadiazine | 15 mg/kg PO q12h135 | |
24-48 mg/kg SC51 | ||
30 mg/kg SC q24h135 | ||
Trimethoprim/sulfamethoxazole | 15 mg/kg PO, IM q12h, or 30 mg/kg PO, IM q24h70 | Prosimians |
50 mg/kg PO q24h29 | Lemurs | |
4 mg/kg PO, SC q8h3,19 | Based on trimethoprim | |
800 mg/animal PO q12h3 | Chimpanzee/based on sulfamethoxazole | |
Tylosin (Tylan, Elanco) | 5 mg/kg PO q12h64 | Clostridium; used in conjunction with metronidazole |
10 mg/kg IM q12h51 | ||
20 mg/kg IM q24h13,19 | Macaque/chronic diarrhea13 | |
Vancomycin | 20 mg/kg IM, IV q12h18 | |
40 mg/kg/day IV continuous infusion36 | ||
500 mg/animal PO q6h3 | Chimpanzees |
Agent | Dosage | Species/Comments |
---|---|---|
Albendazole | 10 mg/kg PO70 | Prosimians/nematodes |
10 mg/kg PO q12h148 | Macaques | |
25 mg/kg PO q12h × 5 days147 | Filaroides | |
28.5 mg/animal PO q12h × 10 days × 3 treatments with a 10-day interval150 | Red ruffed lemurs/subcutaneous cysticercosis; also administer praziquantel 23 mg/animal PO q10d × 3 treatments | |
Amitraz | 250 ppm dip for 2-5 min duration × 4 treatments q14d or until resolution of skin lesions63 | Tamarins/demodectic mange; no haircoat clipping or bathing was performed; animals were not rinsed after treatment; dried with a hot-air dryer; ataxia (transient) may develop |
Azithromycin | 25-50 mg/kg SC q24h112 | Macaques/antimalarial |
40 mg/kg IM q24h first day; 20 mg/kg days 2-518 | Cyptosporidium parvum; limited effectiveness | |
Chloroquine (Aralen, Sanofi) | 10 mg/kg PO, IM once, then 5 mg/kg 6 hr later, then 5 mg/kg q24h × 2 days147 | Malaria (Plasmodium sp); treat concurrently with primaquine |
Dichlorvos | 10-15 mg/kg PO q24h × 2-3 days54 | Gastrointestinal nematodes |
Diethylcarbamazine | 6-20 mg/kg PO q24h × 6-15 days134,147 | Owl monkeys/filariasis (i.e., Dipetalonema) |
20-40 mg/kg PO q24h × 7-21 days65 | ||
50 mg/kg PO q24h × 10 days26 | Squirrel monkeys/filariasis; effective against microfilaria and adults; monkeys were microfilaria negative for 12-24 wk after treatment | |
Doxycycline | 5 mg/kg PO once, then 2.5 mg/kg PO q24h147 | Balantidium |
Fenbendazole | 50 mg/kg PO q24h × 3 days3,29 | Chimpanzees, lemurs |
50 mg/kg PO q24h × 14 days147 | Filaroides | |
Furazolidone | — | Great apes/Giardia; more palatable, but less effective than other agents |
5 mg/kg PO q6h × 7 days133 | Great apes (juveniles) | |
100 mg/animal PO q6h × 7 days133 | Great apes (adults) | |
Iodoquinol (diiodohydroxyquinoline) (Yodoxin, Glenwood) | — | Great apes/minimal absorption; use with other agents for invasive disease; 14-21 days for Balantidium coli; 21 days for Entamoeba |
12-16 mg/kg PO q8h133 | Great apes (infants, juveniles) | |
20 mg/kg PO q12h × 21 days67 | Intestinal amebiasis; Balantidium; for treatment of cystic form, use in combination with metronidazole18 | |
30-40 mg/kg PO q24h × 3-21 days87 | Great apes | |
35-50 mg/kg PO q24h × 21 days133 | Great apes (juveniles) | |
630 mg/animal PO q8h × 20 days3 | Chimpanzees | |
Ivermectin | 0.2 mg/kg PO, SC, IM10,29,65,147 | May repeat in 10-14 days |
0.3 mg/kg PO q7d × 4 treatments66 | Callitrichids/Gongylonema sp | |
Levamisole | 2.5 mg/kg PO q24h × 14 days69 | Prosimians/Physaloptera |
4-5 mg/kg PO q24h × 6 days98 | Saki monkeys/oral spiruridiasis | |
5 mg/kg PO, repeat in 21 days54 | ||
7.5 mg/kg SC, repeat in 14 days51 | ||
10 mg/kg PO147 | Strongyloides, Filaroides, Trichuris | |
Mebendazole | 10-20 mg/kg PO q12h × 3 days, repeat in 14 days69 | Prosimians/gastrointestinal nematodes |
15 mg/kg PO q24h × 3 days147 | Strongyloides, Necator, Pterygodermatitis, Trichuris | |
22 mg/kg PO q24h × 3 days, repeat in 14 days39 | ||
50 mg/kg PO q12h × 3 days3 | ||
70 mg/kg PO q24h × 3 days98 | New World primates/oral spiruridiasis; use treatment periodically | |
100 mg/kg PO q24h for alternating wk98 | Callitrichids/prevention of mortality by acanthocephalan; surgical excision of worms in the intestinal tract is recommended | |
100 mg/kg PO q12h × 3 days3 | Monkeys/Trichuris | |
100 mg/animal PO q12h × 3 days3 | Chimpanzees | |
Mefloquine | 25 mg/kg PO once18 | Antimalarial |
Metronidazole | 17.5-25 mg/kg PO q12h × 10 days147 | Enteric flagellates and amoebas |
30-50 mg/kg PO q12h × 5-10 days93,147 | Balantidium coli | |
35 mg/kg PO q24h104 | Macaques/Trichomonas vaginalis | |
Neoarsphenamine | 20 mg/kg IP q5d96 | Squirrel monkeys/hemobartonellosis; arsenic compound dissolved and diluted in sterile distilled water (0.5 mL/dose) |
Niclosamine | 150 mg/kg once134 | Owl monkeys/intestinal cestodiasis |
166 mg/kg147 | New World primates/cestodes, anoplocephalids | |
Oxibendazole | 10 mg/kg PO q24h66 | Squirrel monkeys/Encephalitozoon cuniculi |
Oxytetracycline | 1500 mg/animal q24h IV, continuous infusion133 | Gorillas/Balantidium coli; nonambulatory animals |
Paromomycin (Humatin, Park Davis) | 10 mg/kg PO q8h × 5-10 days133 | Great apes/Entamoeba |
10-20 mg/kg PO q12h × 5-10 days93 | Balantidium coli | |
12.5-15 mg/kg PO q12h × 5-10 days147 | New World primates/amoebae; minimal absorption; use with other agents for invasive disease | |
25-30 mg/kg q12h × 5-10 days134 | Owl monkeys/enteric amoebas | |
100 mg/kg q24h × 10 days46 | Cercopithecids, pongids/antiprotozoan activity of the drug seems to be related to the protozoal species and the host species | |
Pentamidine isethionate (NebuPent, Fujisawa) | 4 mg/kg IM, IV q24h × 14 days133 | Great apes/Pneumocystis; slow IV infusion; may cause hypotension, cardiac arrhythmias |
Piperazine | 65 mg/kg PO q24h × 10 days54 | |
Praziquantel (Droncit, Bayer) | 5 mg/kg PO, IM, SC once3,19 | |
15-20 mg/kg PO, IM147 | Some cestodes | |
20 mg/kg PO q8h × 3 treatments3 | Chimpanzees | |
23 mg/animal PO q10d × 3 treatments150 | Red ruffed lemurs/subcutaneous cysticercosis; administer with albendazole 28.5 mg/animal PO q12h × 10 days × 3 treatments with a 10-day interval | |
40 mg/kg PO, IM147 | Trematodes | |
Primaquine | 0.3 mg/kg PO q24h × 14 days147 | Plasmodium; treat concurrently with chloroquine |
Pyrantel pamoate | 5-10 mg/kg PO × 3 days70 | Prosimians/nematodes |
6 mg/kg PO29 | Lemurs | |
10 mg/kg PO, repeat in 3 wk3 | Chimpanzees | |
11 mg/kg PO, once147 | Necator; pinworms | |
11 mg/kg PO, repeat in 14 days10 | Owl monkeys | |
Pyrimethamine (Daraprim, Glaxo Wellcome) | 2 mg/kg PO q24h × 3 days, then 1 mg/kg PO q24h × 28 days133,147 | Great apes/Toxoplasma; maximum dosages of 100 mg/animal q24h for days 1-3 and 25 mg/animal q24h for 28 days; treat concurrently with sulfadiazine; supplement with folinic acid |
10 mg/kg q24h112 | Plasmodium; folic acid antagonist; monitor for signs of folic acid deficiency | |
Quinacrine (Atabrine, Winthrop) | 2 mg/kg PO q8h × 7 days133 | Great apes/Giardia; maximum dose of 300 mg/day |
Ronnel (Ectoral, Mallinckrodt) | 55 mg/kg PO q48h × 4 treatments, then q7d × 3 mo147 | Lung mites |
Topically147 | Ectoparasitic mites | |
Sulfadiazine | — | Toxoplasma; treat concurrently with pyrimethamine |
25-50 mg/kg PO q6h133 | Great apes/maximum dose of 6 g/animal/treatment | |
100 mg/kg PO q24h147 | ||
Sulfadimethoxine | 50 mg/kg PO once, then 25 mg/kg q24h147 | Coccidiosis |
Tetracycline | 15 mg/kg PO q8h × 10-14 days133 | Great apes (infants, juveniles)/Balantidium coli |
25-50 mg/kg PO q24h × 5-10 days87 | Great apes/Entamoeba, Balantidium | |
500-1000 mg/animal PO q8h × 10-14 days133 | Great apes (adults)/Balantidium coli | |
Thiabendazole | 50 mg/kg PO q24h × 2 days147 | Strongyloides, Necator |
75-100 mg/kg PO, repeat in 21 days54 | ||
100 mg/kg PO once, repeat in 14 days10 | Owl monkeys | |
Trimethoprim/sulfa | 30 mg/kg PO q6h × 14 days133 | Great apes/Pneumocystis carinii |
Agent | Dosage | Species/Comments |
---|---|---|
Acepromazine | — | See butorphanol and ketamine for combinations |
0.1-0.5 mg/kg PO, SC, IM, IV3 | Chimpanzees (adults) | |
0.2 mg/kg IM34 | Moderate sedation; no immobilization | |
Acetaminophen (Children’s Tylenol Grape Suspension, McNeil Consumer Products) | 5-10 mg/kg PO q6h67 | Macaques, New World primates111/analgesic; antipyretic |
15-20 mg/kg rectal suppository111 | ||
500-1000 mg/animal PO q8h3 | Chimpanzees (adults) | |
Acetylsalicylic acid (aspirin) | — | Analgesic; antiinflammatory; antipyretic |
5-10 mg/kg PO q4-6h3,52 | Monkeys, chimpanzees | |
25 mg/kg rectal suppository109 | ||
Alphaxalone/alphadolone | — | Injectable steroid anesthetic; not available in the United States111 |
10-12 mg/kg IV34 | Short surgical anesthesia (5-10 min)34 | |
10-12 mg/kg IV,37 constant rate infusion of 0.2 mg/kg/min; or 4 mg/kg/20 min intermittent bolus24 | Old World primates/good surgical anesthesia lasting 5-10 min | |
12-18 mg/kg IM, IV34,108,142 | Marmosets, small primates/heavy sedation, anesthesia | |
Atipamezole (Antisedan, Pfizer) | IM use only | Specific α2-adrenergic antagonist; more specific for medetomidine and dexmedetomidine than for xylazine reversal; as a general rule, atipamezole is dosed at the same volume as medetomidine and dexmedetomidine, though they are manufactured at different concentrations |
Atracurium | 0.09-1.5 mg/kg9 IV | Macaques/non-depolarizing neuromuscular blocker; high dose produces histamine-like cardiovascular effects (sudden transient decrease in mean arterial pressure and increase in heart rate) and facial flushing |
Atropine | 0.02-0.05 mg/kg SC, IM, IV109,111 | New World primates/anticholinergic |
0.04 mg/kg SC, IM, IV54 | Macaques, baboons | |
0.05 mg/kg IM34 | Chimpanzees | |
Bupivacaine (0.25%) | 1 mg/kg local infiltration109 | Intercostal nerve block |
Bupivacaine (0.5%) | 1.2 mg/kg epidural45 | Rhesus macaques/epidural analgesia |
Buprenorphine | — | Agonist-antagonist opioid; analgesia61 |
0.005-0.01 mg/kg SC, IM, IV q6-12h33,34,60 | Great apes | |
0.01-0.03 mg/kg IM q6-12h111,117 | Galagos, owl monkeys, squirrel monkeys | |
0.015 mg/kg IM q6-8h111 | New World primates | |
0.02 mg/kg SC q6h111 | New World primates | |
0.3 mg/kg IM q8h3 | Chimpanzees | |
Butorphanol | — | In primates, butorphanol displays a different pattern of receptor pharmacology; rather than being an antagonist at μ receptors, it behaves more as an agonist of intermediate efficacy; receptor binding studies have shown butorphanol has 12-fold μ to κ selectivity and 34-fold μ to δ selectivity;55 may cause profound respiratory depression |
0.01 mg/kg IV q3-4h34 | Duration of action uncertain | |
0.02 mg/kg SC q6h111 | New World species | |
0.02 mg/kg IM111 | Chimpanzees/not to exceed 0.3 mg total | |
0.025 mg/kg IM q3-4h117 | ||
0.05 mg/kg IM q8h3 | ||
0.1-0.2 mg/kg IM q12-48h52 | ||
Butorphanol (B)/acepromazine (A) | 0.02 mg/kg (A) + 0.013 mg/kg IM (B)15 | Macaques/premedication for inhalant anesthesia |
Carfentanil | 0.3 μg/kg IV109 | Rhesus macaques/potent opioid; moderate sedation and analgesia; mild respiratory depression |
Carprofen | 2-4 mg/kg PO, SC q12-24h34,113 | Nonsteroidal antiinflammatory; analgesia |
3-4 mg/kg SC, IV31 | Preoperative | |
Celecoxib | 5 mg/kg19 | Nonsteroidal antiinflammatory; analgesia |
200 mg/animal PO q12-24h3 | Chimpanzees (adults) | |
Chlorpromazine | 1-6 mg/kg PO, IM44 | Preanesthetic |
Deracoxib (Deramaxx, Novartis) | 4 mg/kg PO q24h3 | Nonsteroidal antiinflammatory; analgesia; 2 mg/kg for chronic use |
Dexmedetomidinea (Dexdomitor, Pfizer) | — | α2 agonist that has replaced medetomidinea |
Diazepam | — | Used often as an adjuvant; see ketamine for combination |
0.1-0.5 mg/kg IM52 | Lemurs/prevents ketamine-induced seizures | |
0.25-0.5 mg/kg IM, IV59 | ||
0.5-1 mg/kg PO52 | Sedation; give in small amount of food or drink 30-60 min prior to anesthesia; degree of sedation variable; recovery prolonged | |
1 mg/kg IM34 | Provides insufficient sedation as a single agent | |
Droperidol | 2.5-10 mg IM3 | Chimpanzees (adults)/given 30-60 min prior to procedure |
Droperidol (D)/carfentanil (C) | (D) 2.5 mg PO + (C) 2 μg/kg PO transmucosally74 | Chimpanzees, bonobos (>20 kg)/used to eliminate or minimize stress of darting; followed at 25 min by darting with a combination of tiletamine/zolazepam and naltrexone; (D) was administered in grape juice, and transmucosal (C); was given directly onto oral mucous membrane via hand syringe; respiratory depression with low SpO2; provide supplemental oxygen; warning: use (D)/(C) combination only as a premedication to tiletamine/zolazepam or ketamine anesthesia; the narcotic reversal agent must be given once animal reaches stage 4-5 anesthesia or at 25 min after dosing; naltrexone for reversal, 100× (C) dose in mg |
Enflurane | 1 MAC=1.84%136 | Inhalant anesthetic; isoflurane or sevoflurane preferred |
Etomidate | — | Decreases mean arterial pressure, heart rate, and myocardial contractility; increases systemic arterial compliance |
1 mg/kg IV28 | Induction | |
100 μg/kg/min IV, constant rate infusion28 | Maintenance | |
Fentanyl | — | Fentanyl combinations follow |
0.13, 0.26, or 0.39 μg/kg/min IV constant rate infusion92 | Use with isoflurane MAC (1.53% ± 0.07%); fentanyl sparing effect reduced isoflurane MAC by 19%, 44%, and 59%, respectively | |
5-10 μg/kg/h IV constant rate infusion3 | Chimpanzees | |
5-10 μg/kg IV bolus,109,137 or 10-25 μg/kg/h constant rate infusion81 | Rhesus macaques, baboons/use with isoflurane; side effects include bradycardia, hypotension | |
Fentanyl/droperidol (Innovar-Vet, Janssen) | 0.05-0.1 mL/kg IM, IV67 | Preanesthetic; primates appear to be more sensitive to the drug than dogs;30 high doses produce respiratory depression |
0.1-0.3 mL/kg SC, IM109 | Minor procedures | |
Fentanyl/fluanisone (Hypnorm, Janssen) | 0.3 mL/kg SC, IM109 | Heavy sedation and good analgesia34 |
Fentanyl transdermal patch | 25 μg/kg/h (5-10 kg), 50 μg/kg/h (10 kg) q48-72h3 | Opioid analgesia |
Fentanyl (F)/vecuronium (V)/midazolam (Mi) | 1-5 μg/kg/h + (V) 1-3 mg/kg/h + (Mi) 0.05-0.1 mg/kg/h IV constant rate infusion48 | Orangutans/immobilization |
Flumazenil | 0.025 mg/kg IV56 | Benzodiazepine reversal |
Flunixin meglumine | 0.3-1 mg/kg SC, IV q12-24h52 | Nonsteroidal antiinflammatory; analgesia |
0.5 mg/kg IM q24h29 | Prosimians | |
0.5-2 mg/kg SC, IV q24h34 | ||
2 mg/kg IM q12h3 | ||
Glycopyrrolate | 0.005-0.01 mg/kg IM109 | Anticholinergic |
Ibuprofen | 7 mg/kg PO q12h3,34 | Nonsteroidal antiinflammatory; analgesia |
200-400 mg/animal PO q8h3 | Chimpanzees | |
Isoflurane | 0.5-0.7% isoflurane with 8 μg/kg fentanyl137 | Balanced anesthesia |
1-2% on 100% oxygen; 0.8-1.25% supplemented with 2:1 ration of N2O to oxygen for anesthesia maintenance111 | Baboons | |
1-3% maintenance111 | Marmosets, chimpanzees | |
1 MAC = 1.28-1.46%129,136 | Macaques/inhalant anesthetic; no cardiovascular depression, but profound respiratory depression; 55% MAC reduction when used with 2 mg/kg morphine IV129 | |
3% mask induction and 0.5% maintenance111 | Galagos/10-15 mg/kg ketamine IM for sedation to allow mask placement | |
4-5% for mask induction and 0.5-3% maintenance111 | Squirrel monkeys/induction takes less than 2 min | |
Ketamine | — | Tranquilization; anesthesia; mg/kg dose increases as size of animal decreases; causes seizures in lemurs when used as sole agent (see diazepam, midazolam, ketamine/acepromazine); ketamine combinations follow |
5 mg/kg IM52 | Great apes/immobilization; follow with inhalant anesthetic; used in field immobilization of free-living mountain gorillas; ketamine provides a shorter recovery time than tiletamine/zolazepam125 | |
5-25 mg/kg IM7,34,143 | Larger primates/moderate sedation, immobilization, some analgesia | |
10-15 mg/kg IM52 | New World primates,3 medium-size primates (10-30 kg)/immobilization; follow with inhalant anesthetic34 | |
Ketamine (K)/acepromazine (A) | (K) 4 mg/kg + (A) 0.04 mg/kg IM29 | Lemurs |
Ketamine (K)/diazepam (D) | (K) 15 mg/kg + (D) 1 mg/kg IM32 | Surgical anesthesia with good muscle relaxation lasting 30-40 min33,34 |
Ketamine (K)/medetomidinea (Me) | — | Medetomidine is no longer commercially available, but can be compounded;a has been replaced with dexmedetomidine |
(K) 2-6 mg/kg IM + (Me) 0.03-0.06 mg/kg IM83 | Chimpanzees | |
(K) 5-7.5 mg/kg IM + (Me) 0.033-0.075 mg/kg IM122 | Use higher dosages for smaller primates | |
(K) 5-10 mg/kg IM + (Me) 0.05-0.1 mg/kg IM, IV21 | ||
Ketamine (K)/medetomidinea (Me)/butorphanol (B) | — | Medetomidine is no longer commercially available, but can be compounded;a has been replaced with dexmedetomidine |
(K) 3 mg/kg IM + (Me) 0.04 mg/kg IM + (B) 0.4 mg/kg IM144 | Ring-tailed lemurs/anesthesia; long duration of action; rapid and complete reversibility with specific antagonists | |
Ketamine (K)/midazolam (Mi) | (K) 8 mg/kg IM + (Mi) 0.2 mg/kg4 | Macaques |
(K) 10 mg/kg + (Mi) 1 mg/kg IM40 | Marmosets | |
(K) 15 mg/kg IM + (Mi) 0.05-0.2 mg SC, IM,60 IV62 | ||
Ketamine (K)/xylazine (X) | (K) 10 mg/kg + (X) 0.5 mg/kg IM32 | Surgical anesthesia with good muscle relaxation lasting 30-40 min; xylazine can be reversed with atipamezole,34 or, preferably, yohimbine |
(K) 10-20 mg/kg IM + (X) 3 mg/kg IM3 | New World primates | |
(K) 15-20 mg/kg IM + (X) 1 mg/kg IM3 | Chimpanzees | |
Ketoprofen | 2 mg/kg IM, IV q24h34 | Nonsteroidal antiinflammatory; analgesia |
5 mg/kg IM q6-8h113 | ||
Ketorolac (Torador, Syntex) | 0.5-1 mg/kg SC, IM q8-12h111 | Nonsteroidal antiinflammatory |
15-30 mg/animal113 initially; then 10-15 mg/animal q8h3,111 | Macaques, baboons | |
15-30 mg/animal IM36,111 | Baboons | |
30 mg/animal PO q6h, or single dose 60 mg3,111 | Chimpanzees | |
Medetomidinea | — | α2 agonist; no longer commercially available, but can be compoundeda |
Meloxicam (Metacam, Boehringer Ingelheim) | 0.1-0.2 mg/kg PO, SC q24h34 | Nonsteroidal antiinflammatory; analgesia |
Meperidine | 2-4 mg/kg IM, IV q2-4h34 or q3-4h52,117 | Analgesia; caution: sudden death reported in healthy animals117 |
50-150 mg/animal PO q3-4h3 | Chimpanzees | |
Methohexitone | 10 mg/kg IV34 | Surgical anesthesia, 5-10 min; reduce dose by at least 50% if ketamine is being used as a preanesthetic |
Midazolam | — | See ketamine and fentanyl for combinations |
0.05-0.1 mg/kg IM, IV3 | ||
0.1-0.5 mg/kg IM52 | Lemurs/prevents ketamine-induced seizures | |
0.2-0.4 mg/kg IV bolus109 | Balanced anesthetic technique with fentanyl (1-2 μg/kg IV bolus) | |
1-2.5 mg/animal IV3 | Chimpanzees | |
5 mg/animal IM3 | Chimpanzees | |
Morphine | — | Opioid analgesia; dose dependent respiratory depression; use with care, especially in New World primates; may cause intense pruritis around eyes and nose55 |
0.125-1 mg/kg IV109 | Squirrel monkeys | |
0.5 mg/kg/day IV constant rate infusion110 | Baboons | |
1-2 mg/kg PO, SC, IM, IV q4h34,117 | ||
Morphine, preservative free | 0.01 mg/kg109 | Intrathecal analgesia |
0.1 mg/kg or 0.5 mg/kg/day for 48 hr constant rate infusion109 | Epidural analgesia | |
Nalbuphine | 0.5 mg/kg IM, IV q3-6h52 | |
2.5-5 mg/kg IM q3-4h3 | Agonist-antagonist opioid | |
10 mg/animal SC, IM, IV q3-6h3 prn | Chimpanzees | |
Naloxone | — | Opioid antagonist/reversal; short acting, a second dose may be necessary to avoid the return of respiratory depression111 |
0.015 mg/kg SC, IM, IV111 | Chimpanzees | |
0.1 mg/kg SC, IM, IV prn3 | ||
0.1-0.2 mg/kg IM, IV111 | ||
Naproxen | — | Nonsteroidal antiinflammatory; analgesia; antipyretic |
5 mg/kg PO 24h3 | Chimpanzees | |
10 mg/kg PO q12h65,72 | Lemurs | |
Neostigmine | 0.1 mg/kg IV52 | Anticholinesterase; antidote for nondepolarizing neuromuscular blocking agent; side effect: marked bradycardia; can be used with or without anticholinergic drugs |
Nitrous oxide (N2O) | Up to 60% with O2 (minimum total flow 200 mL/kg/min)60 | Use of O2 analyzer is advisable |
1 MAC = 200%109 | Macaques | |
30% N20 reduced MAC enflurane 1.46% (from 1.84%)130 | Macaques | |
Oxymorphone | — | Opioid analgesia |
0.025 mg/kg SC, IM, IV q4-6h3 | New World primates | |
0.075 mg/kg IM q4-6h111 | New World primates | |
0.15 mg/kg SC, IM, IV q4-6h34,61 | Old World primates | |
1-1.5 mg/animal SC, IM q4h111 | Chimpanzees111 | |
Pancuronium | 0.04-0.1 mg/kg IV109 | Non-depolarizing neuromuscular blocker; requires assisted ventilation; use with caution |
Paracetamol | 5-10 mg/kg PO q6h135 | Analgesia |
Pentazocine | 2-5 mg/kg IM, IV q4h34,52 | Analgesia |
Pentobarbital sodium | — | There is considerable variation between species; severe respiratory depression; inability to modulate depth of anesthesia; prolonged recovery |
15 mg/kg IV slowly to effect111 | New World primates | |
20-30 mg/kg IV; decrease to 11 mg/kg if precede with ketamine 20 mg/kg IM111 | ||
25 mg/kg IV (adults), 15 mg/kg IV (juveniles); slowly to effect111 | Baboons | |
25-35 mg/kg IV33,34 | 30-60 min light surgical anesthesia, but severe respiratory depression often occurs at higher dose; recovery can be prolonged, especially if incremental doses are administered; the dose should be reduced at least 50% if ketamine or other preanesthetics have been used | |
100 mg/animal slow IV111 | Chimpanzees/not to exceed 50 mg/min | |
Pentobarbitone | — | See pentobarbital |
Pethidine (meperidine) | — | See meperidine |
Propofol | 2.5-5 mg kg IV bolus; maintenance with 0.3-0.4 mg/kg/min IV constant rate infusion11,38,109,111,119 | Baboons, macaques |
7-8 mg/kg IV34 | Marmosets, larger primates/induction and maintenance of anesthesia; good surgical anesthesia and rapid smooth recovery38,44 | |
1-2 mg/kg IV bolus, followed by infusion to effect109 | Chimpanzees | |
2 mg/kg IV bolus; maintenance with 0.2 mg/kg/min IV constant rate infusion28 | Decreases mean arterial pressure, heart rate, and myocardial contractility; increases systemic arterial compliance | |
5 mg/kg IV bolus; maintenance with 0.4 mg/kg/min constant rate infusion37 | Macaques | |
Sevoflurane | 1 MAC=2%126 | Macaques |
8% mask induction; 2.5% maintenance80,126 | Garnett’s greater bushbaby/rapid induction and recovery; no significant cardiopulmonary effects; significant decrease in body temperature, WBC count, calcium, and total protein within 30 min of anesthesia | |
Succinylcholine | 2 mg/kg IV50 | Depolarizing neuromuscular agent; requires assisted ventilation; use with caution |
Thiamylal sodium | 15-25 mg/kg IV to effect3,67 | Barbiturate anesthesia |
Thiopental | 3-5 mg kg IV111 | Barbiturate anesthesia; induction agent for inhalation anesthesia; only human-labeled product available |
10-15 mg/kg IV bolus; 5-7 mg/kg IV if combined with ketamine109 | ||
15-17 mg/kg/h IV constant rate infusion109 | ||
15-20 mg/kg IV33 | Barbiturate anesthesia; surgical anesthesia, 5-10 min; reduce dose by at least 50% if ketamine used as premedication | |
25 mg/kg IV to effect67 | ||
Thiopentone | — | See thiopental |
Tiletamine/zolazepam (Telazol, Fort Dodge) | 1-2.5 mg/kg IM3 | New World primates |
1.5-3 mg/kg IM16 | Macaques | |
3-5 mg/kg IM82,123 | Great apes/gorillas can experience severe ataxia during the recovery period, putting them at serious risk of injury55 | |
4-6 mg/kg IM23 | Macaques, baboons, patas monkeys/chemical restraint 45, 60, and 100 min respectively; marked hypothermia reported88 | |
Tramadol | 1-2 mg/kg SC, IV34 | Duration of action uncertain |
2 mg/kg PO q12h34 | ||
Tubocurarine | 0.09 mg/kg IV50 | Non-depolarizing neuromuscular blocking agent; requires assisted ventilation; use with caution |
Vecuronium (Norcuron, Organon) | 0.04-0.06 mg/kg IV111 | Non-depolarizing neuromuscular blocking agent; requires assisted ventilation; has no hemodynamic effects |
Xylazine | — | See ketamine for combination |
0.5 mg/kg IM,3 IV109 | Light to moderate sedation; some analgesia | |
1.1 mg/kg IV3 | Chimpanzees | |
2.2 mg kg IM3 | Chimpanzees | |
Yohimbine | 0.5 mg/kg IV or 1 mg/kg IM111 | Xylazine reversal |
a Medetomidine is no longer commercially available although it can be obtained from select compounding services (i.e., Diamondback Drugs, www.diamondbackdrugs.com; Wildlife Pharmaceuticals, www.wildpharm.com); dosages are listed here as a guide for possible use with dexmedetomidine, an α2 agonist that is the active optical enantiomer of racemic compound medetomidine; dexmedetomidine is used at ½ the dose of medetomidine but the same volume due to higher concentration; although the same effects would be expected as with medetomidine, there is limited data on the efficacy and safety of dexmedetomidine in primates; the effects of the v/v use of the two drugs may not be equivalent, so the dose of dexmedetomidine may need to be adjusted based on clinical response.
Agent | Dosage | Species/Comments |
---|---|---|
Acetylcysteine (Mucomyst, Apothecon) | 50-60 mL/h via nebulization × 30-60 min q12h67 | Mucolytic |
Aminophylline | 10 mg/kg IV29 | Lemurs/bronchodilation |
25-100 mg/animal PO q12h67 | Bronchodilation | |
Atropine sulfate | 0.02-0.05 mg/kg SC, IM, IV109 | Anticholinergic; reduces secretions; prevents bradycardia |
Azathioprine | 1-2 mg/kg PO q24h3 | Immunosuppressive agent; purine antagonist |
Bismuth subsalicylate | — | Intestinal protectant; gastrointestinal ulcers |
10 mg/kg PO q12h25 | ||
17.5 mg/kg PO q6-8h65 | ||
40 mg/kg PO q8-12h3 | ||
Calcium chloride | 10-20 mg/kg IV (slow)118 | Emergency treatment for hypocalcemia (monitor heart rate closely); cardiotonic; reverses aminoglycoside-induced shock |
Calcium gluconate | 200 mg/kg SC, IM, IV118 | Hypocalcemia; hyperkalemia; prophylaxis and therapy of nutritional secondary hyperparathyroidism |
Captopril | 1 mg/kg PO118 | Angiotensin converting enzyme (ACE) inhibitor; vasodilator |
Chlorpheniramine | 0.5 mg/kg q24h PO, in divided doses67 | Antihistamine; H1 receptor antagonist |
Chlorpromazine | 1-3 mg/kg IM95 | Antiemetic |
Cimetidine | 10 mg/kg PO,3 SC, IM q8h14 | H2 receptor antagonist; gastrointestinal ulceration |
Cisapride (Propulsid, Janssen) | 0.2 mg/kg PO q12h57 | Macaques/promotes gastrointestinal motility; limited availability in the United States; can be compounded |
Dexamethasone | 0.25-1 mg/kg PO, IM95 | Antiinflammatory |
≤2 mg/kg PO, IM, IV67 | Antiinflammatory | |
Digoxin | 2-12 μg/kg IM, IV divided q12-24h3 | Maintenance |
Dimercapto-succinic acid (DMSA) (Chemet, McNeil) | 10 mg/kg PO q8h × 5 days, then q12h × 14 days149 | Chimpanzees/lead chelation |
Diphenhydramine | 5 mg/kg IM29 | Lemurs/antihistamine |
5 mg/kg/day PO, IM, IV q6-8h3 | ||
25-50 mg/animal PO, IM, IV q6-8h3 | Chimpanzees (adults) | |
Diphenoxylate/atropine (Lomotil, Searle) | 1 mL/animal PO q8h52 | Opiate; antidiarrheal |
Dobutamine | 2-10 μg/kg/min IV constant rate infusion109 | Adrenergic β1 agonist; increases cardiac output |
Dopamine | 2-5 μg/kg/min IV constant rate infusion109 | Low to moderate doses result in cardiac stimulation (positive inotropic effects) and renal and mesenteric vasodilation; augments cardiac contractility and increases renal perfusion and urinary output |
10 μg/kg/min IV constant rate infusion36 | High doses result in increased peripheral resistance and renal vasoconstriction; bradycardia after cardiac arrest | |
Doxapram | 2 mg/kg IV32 | Respiratory stimulant |
Enalapril (Enacard, Merck) | 0.015-0.125 mg/kg PO q12-24h97 | Western lowland gorillas/antihypertensive |
0.3 mg/kg PO, IV118 | Angiotensin converting enzyme (ACE) inhibitor; balanced vasodilator | |
Ephedrine | 1.25-2.5 mg/kg IV36,109 | Macaques, baboons/vasopressor; hypotension accompanied by bradycardia |
12 mg/kg PO q4h67 | Nasal congestion; bronchoconstriction | |
Epinephrine | 0.2-0.4 mg/kg diluted in 5 mL sterile water, IT36 if ≥3 kg | Cardiac arrest |
0.5-1 mL IV36 | 1:10,000 dilution | |
Erythropoietin, recombinant | 50-100 U/kg SC, IV 3×/wk3 | Treatment of non-regenerative anemia |
Famotidine (Pepcid, Merck) | 0.5-0.8 mg/kg PO q24h99 | Mild gastroenteritis; gastrointestinal ulcers |
Flavored drink, cherry (Koolaid) | PO prn35 | Mix with medication to enhance flavor; mix at 4× normal concentration |
Flavored drink, grape (Syrpalta, Emerson) | PO prn103 | Mix as needed to flavor liquid medications and crushed tablets |
Flavored drink, orange (Tang) | PO prn18,35 | Add electrolyte salts to provide an oral hydration solution |
Fluoxetine (Prozac, Eli Lilly) | 0.45 mg/kg PO q24h138 | Antianxiety |
2 mg/kg PO or nasogastric intubation q24h81 | Rhesus macaques (juveniles) | |
Folic acid | 0.04-0.2 mg/kg PO q24h65 | Supplement during pyrimethamine therapy |
Furosemide | 1-2 mg/kg IV36,134 | Diuresis; heart failure; pulmonary edema |
1-4 mg/kg IV3 | Loop diuretic | |
2 mg/kg PO67 | ||
2-4 mg/kg IM q8h3 | ||
2-4 mg/kg PO q12-24h134 | Owl monkeys | |
Glipizide (Glucotrol, Pfizer) | 1.1 mg/kg PO q24h42 | Titi monkeys/anti-hyperglycemic sulfonylurea; non–insulin-dependent diabetes mellitus |
Glycopyrrolate | 0.005-0.01 mg/kg IM109 | Anticholinergic |
Guanfacine | — | Self-injurious behavior; decreases agitation without profound sedation |
0.3 mg/kg PO, IM q12h × 5-10 days, followed by gradual reduction to 0.15 mg/kg q24h over 30 days90 | Baboons | |
0.5 mg/kg PO, IM q12h × 5-10 days, followed by gradual reduction to 0.25 mg/kg q24h over 30 days90 | Macaques | |
Haloperidol (Haldol, McNeil) | 0.03-0.05 mg/kg IM q12h18 | Macaques/self-injurious behavior |
0.5-2 mg/kg IM118 | Vervets, green monkeys/antianxiety | |
Human chorionic gonadotropin (hCG) | 250 U IM118 | Squirrel monkeys/induced ovulation in 40% of the monkeys |
Hydrocodone bitartrate | 5 mg/animal PO q4-6h3 | Chimpanzees (adults) |
Hydrocortisone sodium succinate | 5 mg/animal IM, IV q12h3 | Chimpanzees (adults) |
Insulin, NPH | 0.25-0.5 U/kg/day SC starting dose65 | Diabetes mellitus; diabetic ketoacidosis |
1.25 U/animal q12h IM139 | Macaques/use combination of short-acting and longer acting insulin (70:30); dose is highly variable (depending on individual, phase of disease, and concurrent medical conditions) and should be adjusted according to standard guidelines | |
Isoproterenol | 0.01-0.03 μg/kg/min IV constant rate infusion106 | Nonselective β-adrenergic agonist |
0.05-2 μg/kg/min IV constant rate infusion3 | ||
Kaolin/pectin | 0.5-1 mL/kg PO q2-6h61 | Intestinal protectant |
Leuprolide | 0.3 mg/kg IM q4wk3 | |
Levothyroxine | 0.01 mg/kg PO q12h79 | Hypothyroidism |
0.05 mg/animal PO q24h78 | Gorillas/hypothyroidism; after initial dosing, institute incremental changes of 0.025 mg q24h at 30-day intervals up to 0.1 mg q24h; monitor TSH and T4 q6-8wk | |
Lidocaine | 20-50 ug/kg/min IV constant rate infusion109 | Ventricular arrthymias; premature ventricular contractions |
1-2 mg/kg IV bolus36 | ||
Loperamide | 0.04 mg/kg PO q8h3 | |
Mannitol (25%) | 0.25-1 g/kg IV bolus over 20 min18 | Osmotic diuresis; reduces intracranial pressure |
Medroxyprogesterone acetate | — | Contraceptive |
5-10 mg/animal PO q24h × 5-10 days3 | ||
150 mg/animal IM q3mo3 | Chimpanzees | |
Metoclopramide | 0.2-0.5 mg/kg IM q8-24h3 | Antiemetic; stimulates motility of upper gastrointestinal tract |
Nitroprusside | 1-4 μg/kg/min IV constant rate infusion109 | Vasodilator; antihypertensive |
Norepinephrine | 0.05-0.1 μg/kg/min IV constant rate infusion36 | Hypotension |
Omeprazole | 0.4 mg/kg PO q12h25 | Macaques/gastric acid suppressant; proton pump inhibitor; use as part of quadruple therapy for Helicobacter pylori infection |
Ondansetron | 1-2 mg/kg PO × 2 doses; prior and after radiation treatment94 | Macaques/antiemetic |
Oxytocin | 0.5-1 U/min IV constant rate infusion3 | Chimpanzees |
2 U/animal IM18 | Macaques/induction of late term abortion (open cervix); repeat q2h maximum 3 treatments; monitor dam closely; provide concurrent analgesia; expulsion of retained placenta (within 12-24 hr); uterine inertia | |
5-20 U/animal IM, IV95 | Uterine inertia | |
5-30 U/animal SC, IV prn3 | Chimpanzees | |
Paroxetine (Paxil, SmithKline Beecham) | 0.3 mg/kg PO q12h138 | Antianxiety |
PGF2 alpha | 1 mg/kg IM q24h3 | Soften cervix prior to chemically inducing labor |
Phenobarbital | 0.6 mg/kg PO q24h69 | Prosimians/anticonvulsant |
Phenylephrine | 1-2 μg/kg IV bolus, followed by 0.5-1 μg/kg/min IV constant rate infusion36,109 | Hypotension |
Phenylephrine (Neo-Synephrine, Winthrop) | Intranasal q6h64 | Nasal congestion |
Phenytoin | 2.5 mg/kg PO q12h, increase3 | Cardiac antiarrhythmic |
Polysulfated glycosaminoglycan (Adequan, Luitpold Pharmaceuticals) | 2 mg/kg IM q3-5d × 2-3 mo3 | Proteolytic enzyme inhibitor used for noninfectious degenerative and/or traumatic arthritis |
Prednisolone sodium succinate (Solu-Delta Cortef, Upjohn) | 1-15 mg/kg IV95 | All species/shock |
10 mg/kg IV29 | Lemurs/shock | |
Prednisone | 0.5-1 mg/kg PO q12h × 3-5 days, then q24h × 3-5 days, then q48h × 10 days, then ½ dose q48h61,65 | Lower doses for pain, inflammation; higher doses for autoimmune, inflammatory bowel disease, etc. |
0.5-2 mg/kg PO3 | ||
Prochlorperazine | 0.12 mg/kg IM, IV3 | Antiemetic |
Protamine | 1 mg/80 U heparin IV109 | Administer slowly to avoid profound hypotension |
4 mg/kg IV48 | 1 mg protamine will neutralize 115 U porcine intestine or 90 U beef lung heparin; may cause hypotension, bradycardia, dyspnea, anaphylaxis; monitor activated partial thromboplastin time and activated clotting time | |
Pyridoxine | 3.5 mg/kg in feed54 | Supplement during isoniazid therapy |
Ranitidine | 0.5 mg/kg PO q12h18 | Anti-ulcerogenic; H2 receptor antagonist |
Sucralfate | 0.5 g/animal PO; maintenance q12h, active ulcer q6h × 4-6 wk3 | Most species/prevent or treat gastric ulcers |
Sulfasalazine | See Table 12-1 | Antibacterial and antiinflammatory properties |
Tolbutamine | 250 mg/animal q24h, then 100 mg/animal q48h49,139 | Capuchin monkeys/oral hypoglycemic agent; non-insulin dependent diabetes mellitus |
Triamcinolone | 0.2-2 mg/kg IM q3d prn105 | |
Trimeprazine (Temaril P, Pfizer) | 1-2 mg/kg PO q6h67 | Antihistamine |
Tryptophan | 100 mg/animal PO q12h141 | Macaques/self-injurious behavior; add to flavored commercial primate treat |
Vitamin C (ascorbic acid) | — | Vitamin C deficiency |
4-10 mg/kg PO q24h65 | ||
4-25 mg/kg PO q24h3 | Chimpanzees | |
25 mg/kg IM q12h × 5 days114 | Macaques | |
30 mg/kg IM q24h3 | ||
30-100 mg/kg PO q24h27 | Macaques (young) | |
Vitamin D3 | 20 U/kg PO q24h3 | Chimpanzees |
250 U/animal PO q24h135 | Marmosets/daily requirement for animals housed in indoor exhibits without access to ultraviolet light | |
2000 U/kg in feed q24h65 | ||
5000 U ergocalciferol depot (sesame oil) IM once at age 4 mo and ergocalciferol 400 U PO q24h from age 4 mo until weaning71 | Chimpanzees (infants), orangutans (infants)/prevention of rickets; monitor clinical signs, radiographic signs, and serum levels of 25(OH) vitamin D3 | |
5000 U ergocalciferol depot IM once and ergocalciferol 400 U PO q24h until resolution of clinical and radiographic abnormalities71 | Chimpanzees (infants), orangutans (infants)/treatment of rickets; monitor clinical signs, radiographic signs, and serum levels of 25(OH) vitamin D3 | |
Vitamin E (E)/selenium (S) | (E) 3.75 U/kg + (S) 1.15 mg/kg IM q3d × 30 days120 | (E)/(S) responsive myopathy, neuropathy |
Vitamin K1 | 1 mg/kg PO, IM q8h3 | Chimpanzees |
1-5 mg/animal IM q24h3 | ||
Zinc | 2.5 μg/animal PO q24h × 3 days3 |